Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $372.7 million.

  • Cartesian Therapeutics' Liabilities and Shareholders Equity fell 1815.03% to $372.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 1202.88%. This contributed to the annual value of $435.0 million for FY2024, which is 4260.71% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $372.7 million for Q3 2025, which was down 1815.03% from $388.9 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Liabilities and Shareholders Equity registered a high of $455.3 million during Q3 2024, and its lowest value of $106.0 million during Q3 2023.
  • In the last 5 years, Cartesian Therapeutics' Liabilities and Shareholders Equity had a median value of $180.5 million in 2021 and averaged $252.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 4051.89% in 2023, then soared by 32940.57% in 2024.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Liabilities and Shareholders Equity stood at $159.9 million in 2021, then grew by 3.75% to $165.9 million in 2022, then soared by 83.89% to $305.0 million in 2023, then surged by 42.61% to $435.0 million in 2024, then fell by 14.33% to $372.7 million in 2025.
  • Its last three reported values are $372.7 million in Q3 2025, $388.9 million for Q2 2025, and $409.1 million during Q1 2025.